GILD Add to watchlist
$137.64 +0.00 (+0.00%)
Pre-Market: $137.64 +0.00 (+0.00%)
Last updated: Apr 20, 2026 13:20
52-Week Range
$137.64
$93.37 $137.64 $157.29

Fundamentals Overview

Gilead Sciences, Inc. is in the middle of its 52-week range with moderate valuation, showing strong upward momentum today.

Valuation moderate

P/E 20.3 PEG 0.01 P/B 7.56 P/S 5.8

Intrinsic value (DCF)

+20.7% upside vs price

Profitability

Net margin 28.9%

Risk (Beta)

0.4 — lower vol

Earnings & growth

EPS $6.79 Rev +2% Profit -28.5% vs prior qtr

BullzEye Analysis

Our composite tilts Buy on technicals (e.g. RSI, ADX, trend), fundamentals, sentiment, sector and index context, and risk.

Composite Signal

Sell
Buy
Buy — 80% confidence Risk: Lower Volatility — Beta 0.4. Diversify and only invest what you can afford to lose.

Supporting (Buy):

DCF +20.7% upside vs price · Analyst grade: B+ · Sentiment improving (1 upgrade) · 3M vs S&P 500: +10.9% · 3M vs Healthcare sector: +18.7%

Not financial advice. For education and research only; do your own research and consider a financial advisor before investing.

Key Stats

Market Cap
$170.84B
P/E (TTM)
20.27
EPS (TTM)
$6.79
Dividend Yield
1.17%
52-Week Range
$93.37 - $157.29
Volume vs Avg
N/A
Beta
0.4

About

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of li...
Sector: Healthcare
Headquarters: US
Employees: 17,600
IPO Date: Jan 1992
Beta: 0.4 (Less volatile than market)

Ratings & Grades at a Glance

Overall rating: B+. Recent institutional grades: majority upgrades. Current institutional positions: Buy: 14, Neutral: 1, Outperform: 1, Overweight: 10, Sector Outperform: 1, Sector Perform: 3.

Financial story & AI narrative

Open this tab to load the financial story.

Valuation & Ratios

Valuation, liquidity, and profitability metrics are consolidated here (including ratios that previously appeared in the Financials story). Trailing (TTM) vs forward-looking (e.g. DCF) is noted on each line where it matters.

DCF vs price: DCF estimate is $166.08; current price is $137.64. That’s a +20.7% gap. When the gap is large (e.g. >20%), that’s divergence; when they’re close, that’s convergence. Differences can reflect growth expectations, sector premiums, or conservative vs. optimistic assumptions. Use DCF as one input alongside technicals and sentiment.

Metric Value
Valuation
P/E (TTM) 20.27
DCF value (model) $166.08 (20.7% upside)
PEG (TTM) 0.01
P/B (TTM) 7.56
P/S (TTM) 5.8
P/FCF (TTM) 18.07
Liquidity & enterprise
Current Ratio (TTM) 1.68
Quick Ratio (TTM) 1.31
Cash Ratio (TTM) 0.64
Profitability
ROE (TTM) N/A
ROA (TTM) N/A
Revenue growth (YoY) N/A
Net margin (TTM) 28.9%
Gross margin (TTM) 80.8%
Operating margin (TTM) 37.37%
Debt to equity (TTM) N/A

Latest News

News loads when you open this tab.

Price Target, Ratings & Grades

Analyst price targets, consensus, rating snapshot, and institutional grades for GILD.

Analyst Sentiment at a Glance

B+ Sentiment Improving
Buy 14Neutral 1Outperform 1Overweight 10Sector Outperform 1Sector Perform 3
1 upgrade, 0 downgrades
Price Target Consensus
Current $137.64
Median $160.00
Consensus $158.53
Low consensus $105.00
High consensus $180.00

Stock Grades (Institutions)

Institution Action Previous Grade New Grade Date
Citigroup maintain Buy Buy 2026-04-13
Morgan Stanley maintain Overweight Overweight 2026-04-10
Needham maintain Buy Buy 2026-02-23
Scotiabank maintain Sector Outperform Sector Outperform 2026-02-11
RBC Capital maintain Sector Perform Sector Perform 2026-02-11
Wells Fargo maintain Overweight Overweight 2026-02-11
Truist Securities maintain Buy Buy 2026-02-11
Cantor Fitzgerald maintain Overweight Overweight 2026-02-11
Needham maintain Buy Buy 2026-02-11
Truist Securities maintain Buy Buy 2026-01-27
Citigroup maintain Buy Buy 2026-01-27
UBS maintain Buy Buy 2026-01-26
Morgan Stanley maintain Overweight Overweight 2026-01-13
Citigroup maintain Buy Buy 2026-01-07
Morgan Stanley maintain Overweight Overweight 2025-12-12
Wells Fargo maintain Overweight Overweight 2025-12-10
Needham maintain Buy Buy 2025-11-13
Truist Securities maintain Buy Buy 2025-11-03
Wells Fargo maintain Overweight Overweight 2025-10-31
Cantor Fitzgerald maintain Overweight Overweight 2025-10-31
Needham maintain Buy Buy 2025-10-31
JP Morgan maintain Overweight Overweight 2025-10-31
RBC Capital maintain Sector Perform Sector Perform 2025-10-31
TD Cowen maintain Buy Buy 2025-10-23
Citigroup maintain Buy Buy 2025-10-08
JP Morgan maintain Overweight Overweight 2025-09-16
BMO Capital maintain Outperform Outperform 2025-08-08
RBC Capital maintain Sector Perform Sector Perform 2025-08-08
UBS maintain Neutral Neutral 2025-08-08
Truist Securities upgrade Hold Buy 2025-08-08